Gülen Gül MERT, M Özlem HERGÜNER, Serdar CEYLANER, Şakir ALTUNBAŞAK, Faruk İNCECİK

Pyridoxine-dependent epilepsy in two Turkish patients in Turkey and review of the literature

Gül-Mert G, İncecik F, Hergüner MÖ, Ceylaner S, Altunbaşak Ş. Pyridoxine-dependent epilepsy in two Turkish patients in Turkey and review of the literature. Turk J Pediatr 2015; 57: 394-397.Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive enzyme defect in the vitamin B6 metabolism characterized by intractable seizures which are usually resistant to all antiepileptic drugs but respond to pharmacological doses of pyridoxine. We present the clinical and molecular genetic findings of two patients with c.1597_1597delG mutations in ALDH7A1 gene. There are different clinical phenotypes in PDE: patients with complete seizure control with pyridoxine and normal development (group 1), patients with complete seizure control with pyridoxine and development delay (group 2), and patients with persistent seizures despite pyridoxine treatment and with development delay (group 3). Our two patients have persistant seizure despite pyridoxine treatment and with development delay. Pyridoxine-dependent epilepsy can be identified in any neonate with signs of encephalopathy and refractory seizures, with no evidence of hypoxic-ischemic damage or other underlying metabolic disturbance. Neurodevelopmental outcomes of patients with PDE is multifactorial; early diagnosis and treatment of these patients is vital.

PDF

___

1. Mills PB, Footitt EJ, Mills KA, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 2010; 133 (Pt 7): 2148- 2159. doi: 10.1093/brain/awq143. Epub 2010 Jun 16.
2. Baxter, P. Pyridoxine dependent and pyridoxine responsive seizures. In: Baxter P. (ed) Vitamin Responsive Conditions in Paediatric Neurology. London: MacKeith Press, 2001: 109-165.
3. Gospe SM Jr. Pyridoxine-dependent seizures: new genetic and biochemical clues to help with diagnosis and treatment. Curr Opin Neurol 2006; 19: 148-153. Review.
4. Plecko B, Paul K, Paschke E, et al. Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat 2007; 28: 19-26.
5. Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006; 12: 307-309.
6. Hunt AD Jr, Stokes J Jr, McCrory WW. Pyridoxine dependency: report of a case of intractable convulsions in an infant controlled by pyridoxine, Pediatrics 1954; 13: 140-155.
7. Stockler S, Plecko B, Gospe SM Jr. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab. 2011; 104: 48-60.
8. Millet A, Salomons GS, Cneude F. Novel mutation in pyridoxine-dependent epilepsy. Eur J Paediatr Neurol 2011; 15: 74-77.
9. Baxter P. Pyridoxine-dependent and pyridoxineresponsive seizures. Dev Med Child Neurol 2001; 43: 416-420.
10. Gordon N. Pyridoxine dependency: an update. Dev Med Child Neurol 1997; 39: 63-65.
11. Nabbout R, Soufflet C, Plouin P. Pyridoxine dependent epilepsy: a suggestive electroclinical pattern. Arch Dis Child Fetal Neonatal Ed. 1999; 81: F125-F129.
12. Gospe SM. Pyridoxine-dependent seizures: findings from recent studies pose new questions. Pediatr Neurol 2002; 26: 181-185. Review.
13. Ulvi H, Müngen B, Yakinci C, et al. Pyridoxinedependent seizures: long-term follow-up of two cases with clinical and MRI findings, and pyridoxine treatment. J Trop Pediatr 2002; 48: 303-306.
14. Perez B, Gonzalez L, Verdu A. Clinical, biomedical, and moleculer studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option. Epilepsia 2013; 54: 239-248.
15. Tlili A, Hentati N, Chaabane R. Pyridoxine-dependent epilepsy in Tunisia is caused by a founder missense mutation of ALDH7A1 gene. Gene 2013; 518: 242-245.
16. Baxter P, Aicardi J. Neonatal seizures after pyridoxine use [letter]. Lancet 1999; 354: 2082-2083.
17. Bok LA, Halbertsma FJ, Houterman S. Long-term outcome in pyridoxine-dependent epilepsy. Dev Med Child Neurol 2012; 54: 849-854.
18. Van Karnebeek CD, Hartmann H, Jaggumantri S, et al. Lysine restricted diet for pyridoxine-dependent epilepsy: first evidence and future trials. Mol Genet Metab 2012; 107: 335-344.
19. Sauer SW, Opp S, Hoffmann GF, et al. Therapeutic modulation of cerebral L-lysine metabolism in a mouse model for glutaric aciduria type I. Brain 2011; 134: 157-170.
20. Mercimek-Mahmutoglu S, Cordeiro D, Cruz V, et al. Novel therapy for pyridoxine dependent epilepsy due to ALDH7A1 genetic defect: l-arginine supplementation alternative to lysine-restricted diet. Eur J Paediatr Neurol 2014; 18 741-746.